Lexeo Therapeutics Inc
LXEO8.190USD
-0.230-2.73%
收盤 11/07, 16:00（美東）報價延遲15分鐘
449.89M總市值
虧損本益比TTM
關於 Lexeo Therapeutics Inc 公司
Lexeo Therapeutics, Inc. 是一家臨牀階段的基因醫學公司，致力於通過應用開創性科學從根本上改變基因定義的心血管疾病和 APOE4 相關阿爾茨海默病的治療方式，從而改變醫療保健。該公司採用分步開發方法，利用早期概念驗證功能和生物標誌物數據來推進心血管和 APOE4 相關阿爾茨海默病項目管線。其管線由針對患者羣體的候選藥物組成。其最先進的心血管候選產品 LX2006 用於治療弗裏德賴希共濟失調 (FA) 心肌病患者，正在正在進行的 I/II 期臨牀試驗 SUNRISE-FA 中進行評估。其第二先進的心血管候選產品 LX2020 用於治療由 PKP2 基因突變 (PKP2-ACM) 引起的心律失常性心肌病，已獲得美國食品藥品監督管理局 (FDA) 的 IND 批准。
Lexeo Therapeutics Inc簡介
公司代碼LXEO
公司名稱Lexeo Therapeutics Inc
上市日期Nov 03, 2023
CEOMr. R. Nolan Townsend
員工數量72
證券類型Ordinary Share
年結日Nov 03
公司地址345 Park Avenue South
城市NEW YORK
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編10010
電話12125479879
網址https://www.lexeotx.com/
公司代碼LXEO
上市日期Nov 03, 2023
CEOMr. R. Nolan Townsend
Lexeo Therapeutics Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Louis Tamayo
Mr. Louis Tamayo
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
45.00K
--
Dr. Eric Adler, M.D.
Dr. Eric Adler, M.D.
Chief Medical Officer and Head of Research
Chief Medical Officer and Head of Research
11.04K
+127.67%
Dr. Jose Manuel Otero, Ph.D.
Dr. Jose Manuel Otero, Ph.D.
Chief Technical Officer
Chief Technical Officer
6.70K
+133.18%
Mr. Van Hauwermeiren
Mr. Van Hauwermeiren
Independent Director
Independent Director
--
--
Mr. Reinaldo M. Diaz
Mr. Reinaldo M. Diaz
Independent Director
Independent Director
--
--
Dr. Brenda Cooperstone, M.D.
Dr. Brenda Cooperstone, M.D.
Independent Director
Independent Director
--
--
Mr. R. Nolan Townsend
Mr. R. Nolan Townsend
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Paula H. J. Cholmondeley
Ms. Paula H. J. Cholmondeley
Independent Director
Independent Director
--
--
Ms. Mette Kirstine Agger
Ms. Mette Kirstine Agger
Independent Director
Independent Director
--
--
Dr. Steven M. (Steve) Altschuler, M.D.
Dr. Steven M. (Steve) Altschuler, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Louis Tamayo
Mr. Louis Tamayo
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
45.00K
--
Dr. Eric Adler, M.D.
Dr. Eric Adler, M.D.
Chief Medical Officer and Head of Research
Chief Medical Officer and Head of Research
11.04K
+127.67%
Dr. Jose Manuel Otero, Ph.D.
Dr. Jose Manuel Otero, Ph.D.
Chief Technical Officer
Chief Technical Officer
6.70K
+133.18%
Mr. Van Hauwermeiren
Mr. Van Hauwermeiren
Independent Director
Independent Director
--
--
Mr. Reinaldo M. Diaz
Mr. Reinaldo M. Diaz
Independent Director
Independent Director
--
--
Dr. Brenda Cooperstone, M.D.
Dr. Brenda Cooperstone, M.D.
Independent Director
Independent Director
--
--
收入明細
FY2023
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
暫無數據
地區USD
名稱
營收
佔比
United States
0.00
0.00%
業務
地區
暫無數據
股東統計
更新時間: 10月29日 週三
更新時間: 10月29日 週三
持股股東
股東類型
持股股東
持股股東
佔比
RA Capital Management, LP
6.85%
Frazier Life Sciences Management, L.P.
6.06%
Balyasny Asset Management LP
5.49%
Janus Henderson Investors
5.05%
Citadel Advisors LLC
4.94%
其他
71.60%
持股股東
持股股東
佔比
RA Capital Management, LP
6.85%
Frazier Life Sciences Management, L.P.
6.06%
Balyasny Asset Management LP
5.49%
Janus Henderson Investors
5.05%
Citadel Advisors LLC
4.94%
其他
71.60%
股東類型
持股股東
佔比
Hedge Fund
29.93%
Investment Advisor/Hedge Fund
14.45%
Venture Capital
14.21%
Investment Advisor
8.03%
Private Equity
6.60%
Research Firm
3.41%
Individual Investor
0.51%
Bank and Trust
0.04%
Family Office
0.02%
其他
22.80%
機構持股
更新時間: 10月5日 週日
更新時間: 10月5日 週日
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
189
48.60M
66.59%
+5.10M
2025Q2
181
40.60M
122.31%
+231.62K
2025Q1
174
34.46M
103.80%
-3.48M
2024Q4
155
35.40M
107.08%
+416.99K
2024Q3
127
33.64M
101.76%
+2.87M
2024Q2
112
31.41M
96.45%
+1.88M
2024Q1
92
30.30M
97.67%
+5.87M
2023Q4
45
23.22M
87.68%
+3.57M
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Frazier Life Sciences Management, L.P.
4.42M
8.19%
--
--
Jun 30, 2025
Balyasny Asset Management LP
4.01M
7.42%
+4.01M
--
Jun 30, 2025
Janus Henderson Investors
3.68M
6.82%
-873.54K
-19.17%
Jun 30, 2025
Citadel Advisors LLC
3.61M
6.68%
+884.60K
+32.48%
Jun 30, 2025
Affinity Asset Advisors LLC
3.59M
6.65%
+2.11M
+142.38%
Jun 30, 2025
Vestal Point Capital, LP
3.23M
5.98%
+2.09M
+184.11%
Jun 30, 2025
Millennium Management LLC
2.84M
5.25%
+902.91K
+46.70%
Jun 30, 2025
Longitude Capital Management Co., LLC
2.77M
5.12%
--
--
Sep 30, 2024
Woodline Partners LP
2.57M
4.76%
+1.74M
+207.30%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月6日 週四
更新時間: 11月6日 週四
機構名稱
佔比
ProShares Ultra Nasdaq Biotechnology
0.04%
Invesco Nasdaq Biotechnology ETF
0.04%
iShares Biotechnology ETF
0.03%
iShares Micro-Cap ETF
0.03%
iShares Russell 2000 Value ETF
0.01%
ProShares UltraPro Russell2000
0.01%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 ETF
0.01%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
查看更多
ProShares Ultra Nasdaq Biotechnology
佔比0.04%
Invesco Nasdaq Biotechnology ETF
佔比0.04%
iShares Biotechnology ETF
佔比0.03%
iShares Micro-Cap ETF
佔比0.03%
iShares Russell 2000 Value ETF
佔比0.01%
ProShares UltraPro Russell2000
佔比0.01%
Proshares Ultra Russell 2000
佔比0.01%
iShares Russell 2000 ETF
佔比0.01%
Global X Russell 2000 ETF
佔比0.01%
ProShares Hedge Replication ETF
佔比0.01%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
